tiprankstipranks
Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility
PremiumCompany AnnouncementsEnanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility
2M ago
Enanta price target lowered to $14 from $16 at Oppenheimer
Premium
The Fly
Enanta price target lowered to $14 from $16 at Oppenheimer
2M ago
Enanta price target lowered to $20 from $26 at Baird
Premium
The Fly
Enanta price target lowered to $20 from $26 at Baird
2M ago
Enanta Pharmaceuticals (ENTA) Q4 Earnings Cheat Sheet
PremiumPre-EarningsEnanta Pharmaceuticals (ENTA) Q4 Earnings Cheat Sheet
2M ago
Enanta’s EDP-323 meets Phase 2a endpoints in respiratory syncytial virus
Premium
The Fly
Enanta’s EDP-323 meets Phase 2a endpoints in respiratory syncytial virus
4M ago
Enanta Pharmaceuticals reports Q3 EPS ($1.07), consensus ($1.45)
Premium
The Fly
Enanta Pharmaceuticals reports Q3 EPS ($1.07), consensus ($1.45)
6M ago
ENTA Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsENTA Upcoming Earnings Report: What to Expect?
9M ago
Enanta appoints Matthew Kowalsky as chief legal officer
Premium
The Fly
Enanta appoints Matthew Kowalsky as chief legal officer
9M ago
Enanta Pharmaceuticals Shareholders Affirm Management Direction
Premium
Company Announcements
Enanta Pharmaceuticals Shareholders Affirm Management Direction
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100